DC-806 is under clinical development by DICE Therapeutics and currently in Phase I for Unspecified Immunological Disorders. According to GlobalData, Phase I drugs for Unspecified Immunological Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the DC-806 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DC-806 overview
DC-806 (S-011806) is under development for the treatment of other IL-17 mediated chronic immunology disorders. It is administered by the oral route. It acts by targeting IL-17.
It was under development for the treatment of plaque psoriasis.
DICE Therapeutics overview
DICE Therapeutics, a subsidiary of Eli Lilly and Co is a pre-clinical stage biopharmaceutical company that develops drugs for the treatment of immunological and chronic diseases. The company is investigating its lead product candidate IL-17 (interleukin 17), an immune-cell-derived cytokine to treat psoriasis and other IL-17 mediated chronic immune disorders and other indications. It is also evaluating drug candidates for the treatment of inflammatory bowel disease, fibrosis and other immune-oncology disorders. The company harnesses its proprietary DELSCAPE platform technology to identify selective oral small molecule antagonists to modulate protein-protein interactions (PPI) targets. DICE Therapeutics is headquartered in South San Francisco, California, the US.
For a complete picture of DC-806’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.